214 related articles for article (PubMed ID: 32076044)
1. Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy.
Ichikawa K; Watanabe Miyano S; Minoshima Y; Matsui J; Funahashi Y
Sci Rep; 2020 Feb; 10(1):2939. PubMed ID: 32076044
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
[TBL] [Abstract][Full Text] [Related]
3. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways
Zhang X; Zhang Y; Jia Y; Qin T; Zhang C; Li Y; Huang C; Liu Z; Wang J; Li K
Cancer Biol Med; 2020 May; 17(2):418-432. PubMed ID: 32587778
[No Abstract] [Full Text] [Related]
5. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
6. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
8. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
9. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
[TBL] [Abstract][Full Text] [Related]
10. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.
Xiao L; Yang S; Hao J; Yuan X; Luo W; Jiang L; Hu Y; Fu Z; Zhang Y; Zou C
Cancer Lett; 2015 Apr; 359(1):148-54. PubMed ID: 25597785
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K
Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280
[TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
13. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
14. Chitosan sulfate inhibits angiogenesis via blocking the VEGF/VEGFR2 pathway and suppresses tumor growth in vivo.
Li Y; Wang W; Zhang Y; Wang X; Gao X; Yuan Z; Li Y
Biomater Sci; 2019 Mar; 7(4):1584-1597. PubMed ID: 30694269
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma.
Sun Q; Wang Y; Ji H; Sun X; Xie S; Chen L; Li S; Zeng W; Chen R; Tang Q; Zuo J; Hou L; Hosaka K; Lu Y; Liu Y; Ye Y; Yang Y
Cell Death Dis; 2022 Aug; 13(8):724. PubMed ID: 35985991
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
[TBL] [Abstract][Full Text] [Related]
17. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
18. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
[TBL] [Abstract][Full Text] [Related]
19. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
20. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.
Zhang J; Liu C; Shi W; Yang L; Zhang Q; Cui J; Fang Y; Li Y; Ren G; Yang S; Xiang R
Oncotarget; 2016 Jul; 7(27):41067-41080. PubMed ID: 27203384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
